Endurant Capital Management’s Krystal Biotech KRYS Stock Holding History

Endurant Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-22,938	Closed	-$1.2M	–	75
2021 Q3	$1.2M	Buy	+22,938	New	+$1.36M	0.27%	47
2019 Q2	–	Sell	-61,155	Closed	-$2.01M	–	66
2019 Q1	$2.01M	Buy	61,155 +48,655	+389%	+$1.15M	0.8%	37
2018 Q4	$260K	Buy	+12,500	New	+$262K	0.14%	48

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Endurant Capital Management's KRYS Position: Q4 2021 in Review

Endurant Capital Management sold out of Krystal Biotech (KRYS) in Q4 2021, closing a stake of 22,938 shares — an estimated $1.2M sold.

Endurant Capital Management first reported a position in KRYS in Q4 2018 and held it in 3 quarters. The position peaked at $2.01M in Q1 2019. 140 funds tracked by Wall St. Rank hold KRYS as of Q4 2021.

Endurant Capital Management reported no remaining Krystal Biotech position as of Q4 2021 after selling out during the quarter.
Endurant Capital Management sold 22,938 Krystal Biotech shares in Q4 2021, an estimated $1.2M.
Endurant Capital Management first reported a position in Krystal Biotech in Q4 2018 and held it in 3 quarters.
Endurant Capital Management's Krystal Biotech position peaked at $2.01M in Q1 2019.
140 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2021.

Based on Endurant Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.